Precision BioSciences (NASDAQ:DTIL) Director Acquires $14,160.00 in Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) Director Geno Germano bought 3,000 shares of the stock in a transaction dated Tuesday, December 16th. The shares were acquired at an average price of $4.72 per share, with a total value of $14,160.00. Following the completion of the purchase, the director directly owned 23,883 shares of the company’s stock, valued at approximately $112,727.76. This represents a 14.37% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Precision BioSciences Trading Down 0.7%

NASDAQ:DTIL opened at $4.49 on Friday. The stock has a market cap of $59.54 million, a price-to-earnings ratio of -0.53 and a beta of 1.11. Precision BioSciences, Inc. has a one year low of $3.61 and a one year high of $8.82. The company has a debt-to-equity ratio of 1.35, a quick ratio of 3.45 and a current ratio of 3.45. The business’s 50-day simple moving average is $5.87 and its 200 day simple moving average is $5.21.

Precision BioSciences (NASDAQ:DTIL) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($1.53). The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $5.40 million. Precision BioSciences had a negative return on equity of 233.77% and a negative net margin of 11,977.36%.During the same quarter in the prior year, the firm earned ($2.25) earnings per share. As a group, sell-side analysts predict that Precision BioSciences, Inc. will post -1.23 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Precision BioSciences in a report on Monday. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $47.00.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Geode Capital Management LLC lifted its holdings in Precision BioSciences by 5.5% in the second quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock worth $326,000 after purchasing an additional 4,025 shares during the period. Bridgeway Capital Management LLC acquired a new stake in shares of Precision BioSciences in the 2nd quarter worth approximately $260,000. Corient Private Wealth LLC bought a new position in shares of Precision BioSciences in the second quarter valued at approximately $425,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Precision BioSciences during the third quarter valued at approximately $72,000. Finally, Vanguard Group Inc. raised its holdings in Precision BioSciences by 21.5% during the third quarter. Vanguard Group Inc. now owns 492,596 shares of the company’s stock worth $2,719,000 after purchasing an additional 87,242 shares in the last quarter. 37.99% of the stock is owned by institutional investors and hedge funds.

Precision BioSciences Company Profile

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.